PROTHENA CORP PUBLIC LTD CO (PRTA) stock: key figures, P/E, revenue and dividend
Health Care · Ireland · ISIN IE00B91XRN20
PROTHENA CORP PUBLIC LTD CO financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 9.68 m USD |
| Gross profit | -125.17 m USD |
| Operating income | -214.64 m USD |
| EBIT | -200.83 m USD |
| Net income | -244.09 m USD |
| Diluted EPS – continuing operations | -4.53 USD |
Full history since 2010, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About PROTHENA CORP PUBLIC LTD CO
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
More stocks
- Huangshan Tourism Development Co Ltd B (900942.SS)
- ValueHD Corp. A (301318.SZ)
- NIOCORP DEVELOPMENTS LTD (NB)
- Intrepid Potash, Inc. (IPI)
- Xuelong Group Co Ltd (603949.SS)
- Donga Socio Holdings (000640.KS)
- Greattown Holdings Ltd B (900940.SS)
- Shanxi Huayang New Material Co Ltd (600281.SS)
- Qijing Machinery (603677.SS)
- Miwon Commerci (002840.KS)
- OXFORD INDUSTRIES INC (OXM)
- Community Healthcare Trust Inc (CHCT)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.